drugset / Trial / NCT06943534

Omalizumab Weight-Based Dosing Efficacy Trial

NCT06943534

Phase 2 Recruiting 30 enrolled Massachusetts General Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.

Timeline

Start
2025-07-03
Primary completion
2027-05-01
Completion
2028-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody 5 mg/kg
Comparator Omalizumab Monoclonal antibody 15 mg/kg

Indications